Details of the Drug Reposition

General Information of This Drug (ID: DM8QM5U)

Drug Name
Anidulafungin   DM8QM5U
Synonyms Ecalta; Eraxis; Anidulafungin [USAN:INN]; Ecalta (TN); Eraxis (TN); LY-303366; V-Echinocandin; VER-002
Therapeutic Class
Antifungal Agents
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
5 Approved Indication(s)
Indication Name Indication ID ICD-11 Status REF
Neuroaspergillosis DISLTCVN N.A. Approved [1]
Aspergillosis DISAIQP2 1F20 Approved [1]
Candidiasis DISIRYMU 1F23 Approved [1]
Mycosis fungoides DIS62RB8 2B01 Approved [1]
Convulsion DIS1CYA2 8A68.Z Approved [2]
------------------------------------------------------------------------------------
2 Investigative Indication(s)
Indication Name Indication ID ICD-11 Status REF
Esophageal candidiasis DISV4PM2 N.A. Investigative [1]
Coronavirus Disease 2019 (COVID-19) DISM7GNX 1D6Y Investigative [3]
------------------------------------------------------------------------------------

References

1 Anidulafungin FDA Label
2 Echinocandins: pharmacokinetic and therapeutic issues. Curr Med Res Opin. 2009 Jul;25(7):1741-50.
3 Suramin, Penciclovir and Anidulafungin bind nsp12, which governs the RNA-dependent-RNA polymerase activity of SARS-CoV-2, with higher interaction energy than Remdesivir, indicating potential in the treatment of Covid-19 infection. April.21.2020. Doi: 10.31219/osf.io/urxwh